-
Publication Venue For
-
Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma..
39:871-879.
2021
-
Targeting MET Amplification with Crizotinib in a Case of Sinonasal Undifferentiated Carcinoma..
39:235-239.
2021
-
Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer..
35:333-344.
2017
-
Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer..
35:32-35.
2017
-
Quality of Life is Similar between Long-term Survivors of Indolent and Aggressive Non-Hodgkin Lymphoma..
34:279-285.
2016
-
Patient-Centered Communication for Discussing Oncotype DX Testing..
34:205-212.
2016
-
Tumor acquisition for biomarker research in lung cancer..
32:291-298.
2014
-
Endothelial colony forming cells (ECFCs) as a model for studying effects of low-dose ionizing radiation: growth inhibition by a single dose..
31:359-364.
2013
-
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma..
31:172-176.
2013
-
Statement of retraction: Hongying Lv, Qicai Li, Wengsheng Qiu, Jinyu Xiang, Hongjun Wei, Hua Liang, Aihua Sui and Jun Liang "Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer"..
31:661-.
2013
-
Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry..
30:679-682.
2012
-
The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost..
30:637-641.
2012
-
Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature..
30:1-12.
2012
-
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer..
29:617-625.
2011
-
New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response..
29:533-541.
2011
-
The genomic relationship between primary breast carcinomas and their nodal metastases..
29:300-307.
2011
-
Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors..
29:56-61.
2011
-
Thrombin expression in prostate: a novel finding..
29:62-67.
2011
-
A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer..
28:978-982.
2010
-
The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features..
28:969-977.
2010
-
Immune signatures predict prognosis in localized cancer..
28:765-773.
2010
-
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy..
28:654-660.
2010
-
Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy..
28:554-559.
2010
-
Anthracyclines in the treatment of early-stage breast cancer: ally or adversary?.
28:217-219.
2010
-
Breast cancer screening: science, society and common sense..
28:1-6.
2010
-
Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer..
27:953-959.
2009
-
Gene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer..
27:885-890.
2009
-
Comparative effectiveness research in oncology: the need for clarity, transparency and vision..
27:593-597.
2009
-
Cancer and thrombosis: back to the future renewed interest in an old problem..
27:472-473.
2009
-
Primary systemic therapy in breast cancer: past lessons and new approaches..
26:1052-1059.
2008
-
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors..
26:794-799.
2008
-
Induction of the human heat shock promoter HSP70B by nutritional stress: implications for cancer gene therapy..
26:553-561.
2008
-
A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer..
26:286-295.
2008